CAMBRIDGE, Mass., Oct. 18, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the third quarter ended September 30, 2017 before the U.S. financial markets open on Wednesday, November 1, 2017.
Management will host a conference call on that date at 10:00 a.m. EDT to discuss these results and provide an update on the company. To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 6492819. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
[email protected]


Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 



